Fly News Breaks for March 4, 2015
RPRX
Mar 4, 2015 | 09:11 EDT
After the FDA announced an update to the testosterone labels, Piper Jaffray says it remains skeptical that the agency will approve Repros Therapeutics' Androxal without evidence of clinical benefit in a Phase 3 trial. Piper notes the FDA in its statement yesterday did not explicitly indicate its views towards obesity-related hypogonadism, the indication for which Repros is seeking approval. It keeps a Neutral rating on the stock.
News For RPRX From the Last 2 Days
There are no results for your query RPRX